Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22324961 | 0.83 | GRIA2 (0.42) | HRH3GRIA2CYP1A2CYP2C9CHRM2 | |
| SCHEMBL22324871 | 0.81 | SMN1; SMN2 (0.48) | HRH3 | |
| SCHEMBL22324765 | 0.79 | L3MBTL1 (0.42) | L3MBTL1LTA4HHRH3GRIA2KCNH2 | |
| SCHEMBL22324948 | 0.77 | L3MBTL1 (0.52) | L3MBTL1LTA4HHRH3GRIA2CYP1A2 | |
| SCHEMBL22325007 | 0.75 | DRD2 (0.45) | CYP1A2CYP2C9 | |
| SCHEMBL22325050 | 0.74 | GRM2 (0.35) | HRH3 | |
| SCHEMBL22340239 | 0.73 | ALDH1A1 (0.44) | — | |
| SCHEMBL22325008 | 0.73 | ALDH1A1 (0.44) | L3MBTL1CYP1A2CYP2C9 | |
| SCHEMBL22324979 | 0.72 | DHFR (0.43) | CYP1A2CYP2C9 | |
| SCHEMBL22325004 | 0.72 | LMNA (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479816-B2 | 20-HETE formation inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-11-25 | — | — | US | disclosed |
| US-20220144797-A1 | 20-HETE FORMATION INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-05-12 | — | — | US | disclosed |
| US-20220144797-A1 | 20-HETE FORMATION INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-05-12 | — | — | US | disclosed |
| WO-2020163689-A1 | 20-HETE FORMATION INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2020-08-13 | — | — | WO | disclosed |
| WO-2020163689-A1 | 20-HETE FORMATION INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2020-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144797-A1 | 20-HETE FORMATION INHIBITORS | CYP4A22, ALOX5, ALOX15 | L3MBTL1 4595/4885LTA4H 66/4885HRH3 2749/4885 |
| US-12479816-B2 | 20-HETE formation inhibitors | CYP4A22, ALOX5, ALOX15 | L3MBTL1 4595/4885LTA4H 66/4885HRH3 2749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.